| Dainippon Sumitomo Pharma Co., Ltd. Patent applications |
| Patent application number | Title | Published |
|---|
| 20120130077 | BENZYL PIPERIDINE COMPOUND - Provided is a new serotonin-reuptake inhibitor that exhibits affinity for serotonin-1A receptors. Said serotonin-reuptake inhibitor is a compound represented by formula (1) or a pharmacologically acceptable salt thereof. In the formula, R | 05-24-2012 |
| 20120122773 | N-SUBSTITUTED-CYCLIC AMINO DERIVATIVE - The present invention provides a compound of formula (I): | 05-17-2012 |
| 20120059012 | 3-(4-AMINOPHENYL)-2-FURANCARBOXYLIC ACID DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF - Disclosed is a compound represented by Formula (I) or a pharmaceutically acceptable salt thereof: | 03-08-2012 |
| 20120034660 | PROCESS FOR PRODUCING OPTICALLY ACTIVE SUCCINIMIDE DERIVATIVES AND INTERMEDIATES THEREOF - A process for producing optically active succinimide derivatives as key intermediates of (3R)-2′-(4-bromo-2-fluorobenzyl)spiro{pyrrolidine-3,4′(1H)-pyrrolo[1,2-a]pyrazine}-1′,2,3′,5(2′H)-tetraone, which comprises the following reaction steps. | 02-09-2012 |
| 20120020924 | NOVEL RECOMBINANT ADENOVIRUS VECTOR HAVING A REDUCED SIDE EFFECT - The present invention provides a novel adenovirus vector for which inflammation during the in vivo administration thereof is alleviated by inhibiting the induction of expression of an adenovirus gene by a foreign promoter inserted into the adenovirus genome, and a method for producing the vector, a cell line for use in the production of the recombinant adenovirus vector, or a gene therapy method using the recombinant adenovirus vector. | 01-26-2012 |
| 20120010264 | NOVEL MEDICAMENT FOR TREATING COGNITIVE IMPAIRMENT - The present invention provides a medicament for preventing and/or treating cognitive impairment, in particular Alzheimer's dementia, comprising 2-methyl-2-[(4-{(1E)-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]prop-1-en-1-yl}benzyl)oxy]propionic acid or a pharmaceutically acceptable salt or solvate thereof. | 01-12-2012 |
| 20110306610 | 9-SUBSTITUTED 8-OXOADENINE COMPOUND - The present invention provides an 8-oxoadenine compound having immunemodulating activities such as an interferon inducing activity and useful as an antiviral agent and antiallergic agent, which is represented by the following formula (1): | 12-15-2011 |
| 20110294804 | NOVEL BICYCLIC HETEROCYCLIC COMPOUND - The invention provides a compound for the treatment or prophylaxis of pathology involving SNS, specifically diseases such as neuropathic pain, nociceptive pain, dysuria, multiple sclerosis and the like. The compound is represented by formula (1) or a pharmaceutically acceptable salt thereof wherein R | 12-01-2011 |
| 20110263848 | PROCESS OF A QUATERNARY AMMONIUM SALT USING PHOSPHATE - The present invention relates to a novel process for preparing quaternary ammonium salt derivatives. | 10-27-2011 |
| 20110263847 | PROCESS OF A QUATERNARY AMMONIUM SALT - The present invention relates to a novel process for preparing quaternary ammonium salt derivatives. | 10-27-2011 |
| 20110263550 | THERAPEUTIC AGENT FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE - Disclosed is a method for the prevention and/or treatment of a chronic obstructive pulmonary disease by administrating a 5-membered cyclic compound represented by the formula below: | 10-27-2011 |
| 20110262566 | NOVEL USEFUL THERAPEUTIC AGENT FOR LOWER URINARY TRACT SYMPTOM - Provided is a therapeutic agent for lower urinary tract symptom consisting of (+)-3-{1-[3-(trifluoromethoxy)benzyl]piperidin-4-yl}-4-phenyl-3,4-dihydro-2(1H)-quinazolinone or a pharmaceutically acceptable salt thereof or a combination of (+)-3-{1-[3-(trifluoromethoxy)benzyl]piperidin-4-yl}-4-phenyl-3,4-dihydro-2(1H)-quinazolinone or a pharmaceutically acceptable salt thereof and a compound selected from the group consisting of α | 10-27-2011 |
| 20110262358 | MOLECULAR MARKER FOR CANCER STEM CELL - A molecular marker for detecting a cancer stem cell in a cell mass which is a subject of interest, wherein the molecular marker can be detected in a cancer stem cell contained in the subject of interest but cannot be detected in a normal cell and a cancer cell that is different from a cancer stem cell; a method for determining the presence or absence of a cancer stem cell in a subject of interest by using the molecular marker as an measure; a kit for determining the presence or absence of a cancer stem cell, which comprises at least a reagent for detecting the molecular marker; a polypeptide encoded by the molecular marker; an antibody capable of recognizing an epitope of an expression product of a gene derived from the molecular marker; a nucleic acid capable of inhibiting the expression of the molecular marker; and a nucleic acid vaccine comprising a gene derived from the molecular marker. | 10-27-2011 |
| 20110237602 | METHOD FOR TREATING SCHIZOPHRENIA AND RELATED DISEASES - The invention relates to a method for treating schizophrenia and/or related diseases comprising administering lurasidone and a mGluR2 ligand to a mammal in need thereof. | 09-29-2011 |
| 20110229506 | METHOD FOR CANCER IMMUNOTHERAPY - A novel compound of the formula (1): | 09-22-2011 |
| 20110224304 | BIPHENYLACETAMIDE DERIVATIVE - The present invention provides a compound of formula (I) or a salt thereof, wherein R | 09-15-2011 |
| 20110217366 | IMMUNOPOTENTIATING COMPOSITION - The present invention provides an immunopotentiating composition which comprises an antigen or antigen-inducing substance, and a carrier comprising a biocompatible material for effectively increasing an immune response derived from an antigen. The present invention further provides a method of producing an antibody by administering said immunopotentiating composition to a mammal or bird, thereby modulating the immune response in said mammal or bird and recovering the antibody produced. | 09-08-2011 |
| 20110212892 | AGENT FOR TREATMENT OF DIABETES - The present invention provides a hypoglycemic agent useful for treating diabetes or other similar diseases which has no adverse effects. Furthermore, the present invention provides a hypoglycemic agent comprising a combination of an antidiabetic drug and 2-methyl-2-[(4-{(1E)-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]prop-1-en-1-yl}benzyl)oxy]propanoic acid or a pharmaceutically acceptable salt thereof. | 09-01-2011 |
| 20110200629 | TUMOR ANTIGEN PEPTIDE AND USE THEREOF - Disclosed is a peptide consisting of the identical amino acid sequence or a substantially identical amino acid sequence to the amino acid sequence depicted in SEQ ID NO:4, wherein the peptide binds to an HLA antigen and is recognized by cytotoxic T cells. The peptide of the present invention can be used in vivo or in vitro as an agent for inducing CTL, that is, cancer vaccine, and exerts therapeutic or ameliorating effects on tumors such as osteosarcoma, renal cancer, and others. The peptide of the present invention is also useful as a tumor marker directed to tumors such as sarcoma, renal cancer, and others. | 08-18-2011 |
| 20110183993 | CYCLOALKANE DERIVATIVE - The present invention relates to a novel cycloalkane derivative which has an excellent psychotropic action. | 07-28-2011 |
| 20110166469 | ELECTROCARDIOGRAM CHART DEVICE AND METHOD THEREOF - An electrocardiogram (ECG) chart device and method capable of easily assisting with the diagnosis of heart disease. Hexagonal radar charts displayed on a screen act as indicators of feature values corresponding to data obtained from each of 12 electrode leads and correlated with the related portions of the heart. For example, a (V1, V2) lead is an indicator of a right ventricle. Each of the radar charts is schematically arranged to correspond with the related portion of the heart. Each vertex of the hexagonal radar charts acts as an indicator of the recognized value. More specifically, each vertex of the radar chart is based on a value obtained by extracting a waveform critical point, a waveform start point, a waveform end point, or the like, of constituent elements of the ECG waveform as the P wave, the Q wave, the R wave, the S wave, the ST segment, the T wave, or the like. Therefore, a user of the ECG radar chart device can intuitively and easily carry out interpretation of ECG data. | 07-07-2011 |
| 20110136801 | Novel Compounds - The present invention provides compounds of formula (I): | 06-09-2011 |
| 20110124659 | CYCLOALKANE DERIVATIVE - The present invention relates to a novel cycloalkane derivative which has a useful psychotropic action with less side effect. | 05-26-2011 |
| 20110118312 | BENZYLPIPERIZINE COMPOUND - Disclosed is a benzylpiperizine compound represented by formula (1) or a pharmaceutically acceptable salt thereof, which is useful as a medicinal agent such as an antidepressant agent. (In the formula (1), R | 05-19-2011 |
| 20110112420 | PAIN JUDGING DEVICE - A device for objectively judging pain is disclosed. A peak-relevant value means ( | 05-12-2011 |
| 20110105615 | TABLET QUICKLY DISINTEGRATING IN THE ORAL CAVITY AND METHOD FOR PRODUCING THE SAME - The present invention relates to a tablet which is rapidly disintegrated in an oral cavity containing an active ingredient at a high content and a production method thereof. That is, the present invention provides a tablet which is rapidly disintegrated in an oral cavity containing an active ingredient in not less than 25% of the total weight, having a disintegration time of within 40 seconds and an absolute hardness of 1.8 N/mm | 05-05-2011 |
| 20110105599 | THERAPEUTIC OR PREVENTIVE AGENTS FOR ISCHEMIC NEUROPATHY - Therapeutic or preventive agents for ischemic nerve injury containing as the active ingredient compounds represented by the general formula [2]: | 05-05-2011 |
| 20110104160 | MEDICAMENT FOR TREATING CANCER - A medicament for treating cancer for use in combination therapy with an anti-HER2 antibody, which comprises amrubicin or a pharmaceutically acceptable salt thereof as an active ingredient. | 05-05-2011 |
| 20110071289 | AMINOPYRAZOLE AMIDE DERIVATIVE - Disclosed is a compound represented by the formula (1) below or a pharmaceutically acceptable salt thereof, which is useful as an agent for prevention and/or treatment of diabetes and the like. | 03-24-2011 |
| 20110053942 | ORALLY DISINTEGRATING TABLETS - The present invention relates to an orally disintegrating tablet containing (1) an active ingredient, (2) mannitol, (3) crystalline cellulose and (4) at least two kinds of particular ingredients selected from the group consisting of low-substituted hydroxypropylcellulose, cornstarch and carmellose, wherein the blending ratio of each ingredient relative to 100 wt % of the disintegrating tablet is (1) 0.01 to 50 wt %, (2) 20 to 86 wt %, (3) 10 to 30 wt %, and (4) 1 to 20 wt % for each particular ingredient and 3 to 60 wt % as the total of the particular ingredients to be blended, and an assembly of (3) crystalline cellulose to be blended has a bulk density of not more than 0.18 g/cm | 03-03-2011 |
| 20110046369 | METHOD FOR PREPARING ADENINE COMPOUND - A method for producing adenine compound (1): | 02-24-2011 |
| 20110028715 | NOVEL ADENINE COMPOUND - A novel adenine compound represented by the formula (1): | 02-03-2011 |
| 20110028535 | OLIGONUCLEOTIDES-TRANSFERRING PREPARATIONS - Preparations for transferring efficiently oligonucleotides necessary in antisense therapy or the like into animal cells so as to be useful in treatment for various diseases, which comprises a collagen as an essential component are provided. | 02-03-2011 |
| 20110021452 | LYOPHILIZED PREPARATION OF STABILIZED ANTHRACYCLINE COMPOUNDS - The present invention provides a lyophilized preparation of amrubicin, which contains L-cysteine or a salt thereof and has a water content of 0 to about 4% by weight within the preparation, and is stable even in a long-term storage, and further provides a method for production of said preparation. Said preparation is useful as a chemotherapeutic agent for cancers. | 01-27-2011 |
| 20110009433 | BICYCLIC PYRROLE COMPOUND - Disclosed is a compound composed of an easily-handleable crystal form and having storage stability that is practical enough to be used as an active ingredient of a pharmaceutical product. Specifically disclosed is 6-[(3R)-3-aminopiperidin-1-yl]-5-(2-chloro-5-fluorobenzyl)-1,3-dimethyl-1H-pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione monohydro chloride hemihydrate. | 01-13-2011 |
| 20100298364 | SALTS 756 - The invention provides salts of 4-(dimethylamino)butyl 2-(4-((2-amino-4-methyl-6-(pentylamino)pyrimidin-5-yl)methyl)phenyl)acetate, pharmaceutical compositions containing them and their use in therapy. | 11-25-2010 |
| 20100286389 | STABLE CRYSTAL OF BETA-LACTAM COMPOUND - A stable crystal (Form I crystal) of (4R,5S,6S)-6-[(1R)-1-hydroxyethyl]-4-methyl-3-({4-[(5S)-5-methyl-2,5-dihydro-1H-pyrrol-3-yl]-1,3-thiazol-2-yl}thio)-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid which has preferable properties and a process for preparation Form I crystal which is characterized of desolvating a solvated crystal of its compound. | 11-11-2010 |
| 20100286286 | ORALLY DISINTEGRATING TABLET - The invention provides an orally disintegrating tablet that has both adequate tablet hardness and rapid disintegrability in the oral cavity, and that undergoes minor hardness reduction and maintains good oral disintegrability even when preserved under moist conditions. In particular, the invention relates to an orally disintegrating tablet containing (a) crystalline cellulose, (b) a calcium hydrogen phosphate compound, (c) a natural starch and (d) a lubricant, wherein the blending ratio to 100 wt % of the disintegrating tablet is (a) 9 to 60 wt %, (b) 16 to 60 wt %, (c) 3 to 40 wt % and (d) 0.01 to 1.8 wt %. | 11-11-2010 |
| 20100238192 | BIOLOGICAL INFORMATION TREND DISPLAY DEVICE AND METHOD THEREOF - A biological information trend display device and method which allow the trend and an abnormal value of biological information to be checked with ease are provided. When a curve ( | 09-23-2010 |
| 20100198038 | ELECTRODE SHEET AND PROCESS FOR PRODUCING ELECTRODE SHEET - [Problem to be Solved] To provide an electrode sheet which has ensured electroconductivity of a wiring layer.
| 08-05-2010 |
| 20100190768 | NOVEL FUSED PYROLE DERIVATIVE - The present invention relates to a compound represented by the formula (1) which is useful as a glucocorticoid receptor function regulating agent, an anti-inflammatory agent or an antidiabetic agent, or a pharmaceutically acceptable salt thereof: | 07-29-2010 |
| 20100179118 | CYCLIC AMINOALKYLCARBOXAMIDE DERIVATIVE - The present invention relates to a compound represented by the following formula (I), which is useful as an antiallergic agent and/or an anti-inflammatory agent, or a physiologically acceptable salt thereof and the like: | 07-15-2010 |
| 20100160304 | AROMATIC SULFONE COMPOUND AS ALDOSTERONE RECEPTOR MODULATOR - The present invention provides a compound represented by the following formula (I): | 06-24-2010 |
| 20100113792 | BENZYLPIPERIZINE COMPOUND - Disclosed is a benzylpiperizine compound represented by formula (1) or a pharmaceutically acceptable salt thereof, which is useful as a medicinal agent such as an antidepressant agent. (In the formula (1), R | 05-06-2010 |
| 20100098756 | ORAL DISINTEGRATING TABLET - An oral disintegrating tablet containing (1) D-mannitol, (2) an active ingredient, (3) one or more disintegrating agents selected from the group consisting of crospovidone and carmellose, and (4) one or more lubricants selected from the group consisting of sodium stearyl fumarate and sucrose esters of fatty acids. The oral disintegrating tablet of the present invention has some excellent properties of (1) allowing easy production in a common facility without necessitating a specialized pharmaceutical technique, (2) having an appropriate strength that does not breakdown in the process of distribution, (3) having a fast disintegrating ability in the oral cavity, and (4) also having excellent ingestion feel such as greatly reduced bitterness or gritty feel; therefore, the tablet can be suitably used as a dosage form that is suitable for aged individuals, children, and seriously ill patients. | 04-22-2010 |
| 20100093998 | NOVEL ADENINE COMPOUND - A novel adenine compound represented by the formula (1): | 04-15-2010 |
| 20100093875 | GRANULAR PREPARATION PREVENTED FROM CAKING - The present invention provides a granular preparation that resists caking during preservation, namely, a granular preparation characteristically with suppressed caking, which comprises an active ingredient other than biguanide, a sugar or a sugar alcohol, an organic acid and a particular water-soluble polysaccharide; and a method of suppressing caking of a granular preparation, which includes adding a particular water-soluble polysaccharide to the active ingredient, sugar or sugar alcohol and organic acid. | 04-15-2010 |
| 20100076203 | Succinic acid diester derivative, process for production thereof, and use of the derivative in the production of pharmaceutical preparation - The present invention provides with a process of preparing an optically active succinimide derivative, which is a key intermediate for production of ranirestat. A compound (3) is easily prepared by treating the derivative of succinic acid diester of the formula (2): | 03-25-2010 |
| 20100062010 | NOVEL PEPTIDE COMPOUND - A novel compound of the formula (1): | 03-11-2010 |
| 20100056497 | AMIDE DERIVATIVE - The present invention relates to a compound of the formula (I) being useful as a renin inhibitor, or a pharmaceutically acceptable salt thereof. | 03-04-2010 |
| 20100009976 | BENZOTHIAZIN-3-ONE COMPOUND AND INTERMEDIATE THEREFOR - A medicine which contains as an active ingredient a benzothiazin-3-one-compound represented by the formula (1): | 01-14-2010 |
| 20100004464 | Method for producing succinimide compound - There is provided a method for producing a succinimide compound. The method for producing a succinimide compound of formula (3) comprises reacting an aminomalonic ester compound of formula (1) with a compound of formula (2) in a solvent in the presence of a base, wherein an alcohol is used as the solvent and an alkali metal alkoxide is used as the base. | 01-07-2010 |
| 20100003729 | Method for producing optically active succinimide compound - There is provided a novel method for producing an optically active succinimide compound which is a useful compound utilized as an intermediate raw material for pharmaceutical products or the like. The method for producing an optically active succinimide compound of formula (2) comprises processing a racemic compound of a succinimide compound of formula (1) in the presence of a hydrolase to selectively hydrolyze one of the enantiomers, and subjecting to a post-treatment. | 01-07-2010 |
| 20090311729 | DIAGNOSIS OF ACUTE ENTEROCOLITIS BY DETERMINATION OF INTESTINAL FATTY ACID-BINDING PROTEIN IN THE BLOOD - The present invention provides a quick and convenient determination method and a determination reagent for acute enterocolitis, which can determine acute enterocolitis quantitatively and objectively. | 12-17-2009 |
| 20090285834 | NOVEL MEMORY CTL INDUCTION POTENTIATOR - The present invention relates to a memory CTL induction enhancer comprising a combination of substance (b) with substance (a) and/or substance (c), wherein substance (a) is an activator of antigen-presenting cells, substance (b) is an inducer of homeostatic proliferation after induction of lymphopenia, and substance (c) is a suppressor of regulatory T cells. | 11-19-2009 |
| 20090192129 | BICYCLIC PYRROLE DERIVATIVES - Compounds represented by the general formula (I), prodrugs thereof, or pharmaceutically acceptable salts of both are provided as compounds which have high DPP-IV inhibiting activity and are improved in safety, toxicity and so on: (I) | 07-30-2009 |
| 20090186083 | METHOD FOR STABILIZATION OF ISOXAZOLE COMPOUND | 07-23-2009 |
| 20090176800 | IN VIVO SCREENING METHOD OF THERAPEUTIC AGENT FOR MEMORY/LEARNING DYSFUNCTIONS BY SCHIZOPHRENIA - A method of evaluating memory/learning functions with the use of a model with glutamic acid N-methyl-D-aspartate (NMDA) type receptor hypofunction as an animal model for schizophrenia and with the use of reference memory task, wherein there has been found concrete means for detecting any differences in activity between typical anti-psychosis drugs and atypical anti-psychosis drugs is found. | 07-09-2009 |
| 20090149483 | BICYCLIC PYRROLE DERIVATIVES - Compounds represented by the general formula (I), prodrugs thereof, or pharmaceutically acceptable salts of both are provided as compounds which have high DPP-IV inhibiting activity and are improved in safety, toxicity and so on: (I) | 06-11-2009 |
| 20090136572 | EMULSIFIED COMPOSITION FOR DILUTION AND CANCER VACCINE COMPOSITION - Provided is an emulsified composition for diluting a cancer antigen peptide or a dimer thereof. Also provided is a novel cancer vaccine composition or specific CTL inducer that efficiently induces CTL irrespective of the type of cancer antigen peptide when mixing the emulsified composition for dilution and a water phase comprising a cancer antigen peptide or a dimer thereof. | 05-28-2009 |
| 20090131412 | NOVEL 2-QUINOLONE DERIVATIVE - A compound represented by the formula (1) or a pharmaceutically acceptable salt thereof which has a therapeutic or prophylactic effect on an SNS-related disease such as neuropathic pain. (1) wherein R | 05-21-2009 |
| 20090131398 | OXINDOLE DERIVATIVE AS FEEDING CONTROL AGENT - Disclosed is a compound represented by the formula (1) below, a prodrug thereof or a pharmaceutically acceptable salt of either, which is useful as a therapeutic, preventive or ameliorating agent for diabetes and the like. | 05-21-2009 |
| 20090130215 | GRANULAR PREPARATION CONTAINING BIGUANIDE COMPOUND - A granular preparation containing a biguanide compound and a solidification-preventive agent does not solidify during storage and can avoid the difficulty in dosing. | 05-21-2009 |
| 20090118263 | Novel Adenine Compound - An adenine compound represented by the formula (1): (1) [wherein A | 05-07-2009 |
| 20090104691 | NOVEL RECOMBINANT ADENOVIRUS VECTOR HAVING A REDUCED SIDE EFFECT - The present invention provides a novel adenovirus vector for which inflammation during the in vivo administration thereof is alleviated by inhibiting the induction of expression of an adenovirus gene by a foreign promoter inserted into the adenovirus genome, and a method for producing the vector, a cell line for use in the production of the recombinant adenovirus vector, or a gene therapy method using the recombinant adenovirus vector. | 04-23-2009 |
| 20090074861 | STABLE TABLET CONTAINING DROXIDOPA - A tablet containing droxidopa as an active ingredient in a proportion of 20-80 wt % relative to the total weight of the tablet, and characteristically containing at least one excipient selected from mannitol, lactose, erythritol, glucose, sucrose, crystalline cellulose, and corn-derived starch is provided. In addition, a preparation containing corn-derived processed starch or polyvinyl alcohol as a binder and the like, which is a stable tablet containing droxidopa as an active ingredient, is provided. | 03-19-2009 |
| 20090062184 | FINE PARTICULATE PREPARATION COMPRISING COMPLEX OF NUCLEIC ACID MOLECULE AND COLLAGEN - The present invention relates an additive comprising at least one substance selected from arginine, trometamol, meglumine, lysine, histidine, monoethanolamine, diethanolamine, triethanolamine, succinic acid, citric acid, tartaric acid, lactic acid, and salts thereof, which is useful in the prevention of aggregation of fine particulate complexes of a nucleic acid and collagen, and the production of a preparation comprising particulate complexes of controlled size which is suited for transporting a nucleic acid into cells. | 03-05-2009 |
| 20090012408 | GARMENT FOR BIOINFORMATION MEASUREMENT HAVING ELECTRODE, BIOINFORMTION MEASUREMENT SYSTEM AND BIOINFORMATION MEASUREMENT DEVICE, AND DEVICE CONTROL METHOD - The present invention provides a garment for measuring biological information, a biological information measurement system, a biological information measurement device and a method of controlling thereof capable of measuring biological information with accuracy regardless of variations of the constitution of each examinee. When an examinee wears a biological information measurement shirt | 01-08-2009 |
| 20080319177 | RECOMBINASE-EXPRESSING CELLS - In accordance with the present invention, there are provided cells for expressing recombinase Cre in the presence of recombinase FLP in a FLP-dependent manner, methods of expressing recombinase Cre by introducing recombinase FLP into the above cells, methods of producing recombinant viral vectors using cells that express recombinase Cre in the presence of recombinase FLP in a FLP-dependent manner, and methods of producing recombinant adenovirus vectors using the above method of producing Cre and the above method of producing recombinant viral vectors. | 12-25-2008 |
| 20080318922 | Bicyclic Pyrrole Derivatives - Compounds represented by the general formula (I), prodrugs thereof, or pharmaceutically acceptable salts of both are provided as compounds which have high DPP-IV inhibiting activity and are improved in safety, toxicity and so on: (I) | 12-25-2008 |
| 20080311212 | CRYSTALLINE ISOXAZOLE DERIVATIVE AND PHARMACEUTICAL PREPARATION THEREOF - Crystalline 3-[(1S)-1-(2-fluorobiphenyl-4-yl)ethyl]-5-{[amino(morpholin-4-yl)methylene]amino}-isoxazole that exhibits the following angle of diffraction (2θ) and relative intensity in a powder X-ray diffraction pattern, is very easy to handle and stable in a process of its formulation into a pharmaceutical preparation. | 12-18-2008 |
| 20080299548 | Gene Expressed Specifically in Es Cells and utilization of the Same - The present invention relates to an ES cell detection marker containing a polynucleotide derived from any one of ECAT15-1 gene, ECAT15-2 gene, ECAT16 gene, Rnf17 gene and LOC380905(TDRD4) gene. | 12-04-2008 |
| 20080274914 | Screening Method for Somatic Cell Nuclear Reprogramming Substance - The present invention provides a screening method for somatic cell nuclear reprogramming substances, which comprises (a) a step for bringing into contact with each other a somatic cell comprising a gene wherein a marker gene is present at a position permitting expression control by the expression control region of an ECAT gene, and a test substance, and (b) a step following the aforementioned step (a), for determining the presence or absence of the emergence of cells expressing the marker gene, and selecting a test substance allowing the emergence of the cells as a somatic cell nuclear reprogramming substance candidate, and the like. | 11-06-2008 |
| 20080255121 | Combination Drug for Treating Autoimmune Disease - It is intended to provide a combination drug for preventing and/or treating an autoimmune disease. More specifically speaking, a combination drug for preventing and/or treating an autoimmune disease which contains a CaMKII inhibitor and a disease-modifying antirheumatic drug; a medicinal composition, a commercial package, a kit, etc. for the combination; an enhancer for the effect of preventing and/or treating an autoimmune disease of a disease-modifying antirheumatic drug which contains a CaMKII inhibitor as the active ingredient; a method of screening a CaMKII inhibitor appropriately usable in combination, and so on. | 10-16-2008 |
